[Federal Register: November 23, 2001 (Volume 66, Number 226)]
[Notices]               
[Page 58746]
From the Federal Register Online via GPO Access [wais.access.gpo.gov]
[DOCID:fr23no01-61]                         

-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

 
Blood Products Advisory Committee; Notice of Meeting

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

    This notice announces a forthcoming meeting of a public advisory 
committee of the Food and Drug Administration (FDA). The meeting will 
be open to the public.
    Name of Committee: Blood Products Advisory Committee.
    General Function of the Committee: To provide advice and 
recommendations to the agency on FDA's regulatory issues.
    Date and Time: The meeting will be held on December 13, 2001, from 
8 a.m. to 5:30 p.m. and on December 14, 2001, from 8 a.m. to 3:30 p.m.
    Location: Hilton Silver Spring Hotel, 8727 Colesville Rd., Silver 
Spring, MD.
    Contact: Linda A. Smallwood, Center for Biologics Evaluation and 
Research (HFM-302), Food and Drug Administration, 1401 Rockville Pike, 
Rockville, MD 20852, 301-827-3514, or FDA Advisory Committee 
Information Line, 1-800-741-8138 (301-443-0572 in the Washington, DC 
area), code 19516. Please call the Information Line for up-to-date 
information on this meeting.
    Agenda: On December 13, 2001, the following committee updates are 
tentatively scheduled: Transmissible spongiform encephalopathies (TSE) 
guidance, Centers for Disease Control and Prevention workshop on factor 
VIII, update on disaster response, and compliance quality control 
oversight. In the morning, the committee will hear presentations, 
discuss and make recommendations on potential concerns for simian foamy 
virus (SFV) transmission by blood and blood products. In the afternoon, 
the committee will hear presentations, discuss and make recommendations 
on the leukocyte reduction guidance. On December 14, 2001, the 
committee will hear presentations and discuss and make recommendations 
on human cells, tissues and cellular and tissue-based products: Risk 
factors for semen donation.
    Procedure: Interested persons may present data, information, or 
views, orally or in writing, on issues pending before the committee. 
Written submissions may be made to the contact person by December 3, 
2001. Oral presentations from the public will be scheduled between 
approximately 12 noon and 12:30 p.m., and between approximately 3:45 
p.m. and 4:45 p.m. on December 13, 2001; and between approximately 
11:30 a.m. and 1 p.m. on December 14, 2001. Time allotted for each 
presentation may be limited. Those desiring to make formal oral 
presentations should notify the contact person before December 3, 2001, 
and submit a brief statement of the general nature of the evidence or 
arguments they wish to present, the names and addresses of proposed 
participants, and an indication of the approximate time requested to 
make their presentation.
    Notice of this meeting is given under the Federal Advisory 
Committee Act (5 U.S.C. app. 2).

    Dated: November 15, 2001.
Linda A. Suydam,
Senior Associate Commissioner.
[FR Doc. 01-29226 Filed 11-21-01; 8:45 am]
BILLING CODE 4160-01-S